Stockreport

Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin

HEMISPHERX BIOPHARMA  (HEB) 
NASDAQ:AMEX Investor Relations: hemispherx.net/mobile/investor-relations.php
PDF OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 [Read more]